Could pharmacogenetics play a role as predictor in treatment of depressive disorders?
作者信息
Lee Min-Soo
出版信息
World J Biol Psychiatry. 2007;8(1):2-3. doi: 10.1080/15622970601183452.
PMID:17366343
Abstract
摘要
相似文献
1
Could pharmacogenetics play a role as predictor in treatment of depressive disorders?药物遗传学能否在抑郁症治疗中发挥预测作用？
World J Biol Psychiatry. 2007;8(1):2-3. doi: 10.1080/15622970601183452.
2
Pharmacogenetics in modern psychiatry.现代精神病学中的药物遗传学
Psychiatr Danub. 2007 Sep;19(3):231-3.
3
Pharamacogenetics and antidepressant treatment in integrative psychiatry perspective.整合精神病学视角下的药物遗传学与抗抑郁治疗
Psychiatr Danub. 2008 Sep;20(3):399-401.
4
Insights and barriers to clinical use of serotonin transporter pharmacogenetics in antidepressant therapy.5-羟色胺转运体药物遗传学在抗抑郁治疗临床应用中的见解与障碍
Pharmacogenomics. 2018 Feb;19(3):167-170. doi: 10.2217/pgs-2017-0196. Epub 2018 Jan 12.
5
Pharmacotherapeutic approaches to treatment-resistant depression.难治性抑郁症的药物治疗方法。
JAAPA. 2003 Mar;16(3):32-4, 37-8, 40 passim.
6
Serotonin transporter polymorphism and response to SSRIs in major depression and relevance to anxiety disorders and substance abuse.血清素转运体基因多态性与重度抑郁症中对选择性5-羟色胺再摄取抑制剂（SSRI）的反应以及与焦虑症和药物滥用的相关性
Pharmacogenomics. 2000 Aug;1(3):335-41. doi: 10.1517/14622416.1.3.335.
7
Pharmacogenomics and antidepressant drugs.药物基因组学与抗抑郁药物
Ann Med. 2006;38(2):82-94. doi: 10.1080/07853890600551045.
8
[The influence of genetic variations on the effect of selective serotonin reuptake inhibitors].[基因变异对选择性5-羟色胺再摄取抑制剂疗效的影响]
Ugeskr Laeger. 2007 Apr 16;169(16):1439-41.
9
Anticipated outcomes from introduction of 5-HTTLPR genotyping for depressed patients: an expert Delphi analysis.对抑郁症患者采用5-羟色胺转运体基因启动子区域多态性（5-HTTLPR）基因分型的预期结果：一项专家德尔菲分析
Public Health Genomics. 2010;13(7-8):406-14. doi: 10.1159/000313467. Epub 2010 Jul 6.
10
TORDIA: unique opportunity to explore half-life theory.托迪亚：探索半衰期理论的独特机遇。
Am J Psychiatry. 2009 Aug;166(8):936; author reply 936-7. doi: 10.1176/appi.ajp.2009.09050601.
Zotero 插件